Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992971 | 1.00 | ACE2 (0.50) | ACE2S1PR2S1PR1GPR84MAPT | |
| SCHEMBL4001493 | 1.00 | ACE2 (0.50) | ACE2S1PR2S1PR1GPR84MAPT | |
| SCHEMBL3996933 | 0.89 | S1PR2 (0.45) | ACE2S1PR2S1PR1GPR84SLC1A3 | |
| SCHEMBL288356 | 0.86 | S1PR2 (0.57) | S1PR2S1PR1GPR84SLC1A3SLC1A2 | |
| SCHEMBL6466558 | 0.86 | S1PR2 (0.57) | S1PR2S1PR1GPR84SLC1A3SLC1A2 | |
| SCHEMBL5496400 | 0.86 | S1PR2 (0.57) | S1PR2S1PR1GPR84SLC1A3SLC1A2 | |
| SCHEMBL2909702 | 0.85 | S1PR2 (0.46) | ACE2S1PR2S1PR1GPR84MAPT | |
| SCHEMBL3958660 | 0.85 | S1PR2 (0.46) | ACE2S1PR2S1PR1GPR84MAPT | |
| SCHEMBL584298 | 0.85 | S1PR2 (0.46) | ACE2S1PR2S1PR1GPR84MAPT | |
| SCHEMBL122149 | 0.85 | S1PR2 (0.46) | ACE2S1PR2S1PR1GPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| CN-100462351-C | Amino acids having affinity for the alpha 2 delta protein | WARNER LAMBERT CO (US) | 2009-02-18 | — | — | CN | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| CN-1856301-A | Curable beta-amino acid | WARNER LAMBERT CO (US) | 2006-11-01 | — | — | CN | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| CN-1817854-A | Amino acids with affinity for the alpha-2-delta protein | WARNER LAMBERT CO (US) | 2006-08-16 | — | — | CN | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| EP-1670452-A2 | METHOD OF USE OF AMINOACIDS HAVING AFFINITY FOR THE A2D PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | disclosed |
| CN-1653036-A | Amino acids having affinity for the alpha 2 delta protein | WARNER LAMBERT CO (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ACE2 815/4885S1PR2 3566/4885S1PR1 4618/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | ACE2 1053/4885S1PR2 3395/4885S1PR1 4348/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ACE2 674/4885S1PR2 3782/4885S1PR1 4623/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | ACE2 712/4885S1PR2 3482/4885S1PR1 4491/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ACE2 815/4885S1PR2 3566/4885S1PR1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.